Biotechnology News

沃尔瑟姆，马萨诸塞州, Oct. 13, 2026 (GLOBE NEWSWIRE) --...

沃尔瑟姆，马萨诸塞州, Oct. 13, 2026 (GLOBE NEWSWIRE) --...

AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy candidate BNT113 plus pembrolizumab compared with...

Die klinische Phase-2/3-Studie AHEAD-MERIT erreichte nicht den ersten dualen primären Endpunkt des progressionsfreien Überlebens für den mRNA-Krebsimmuntherapiekandidat BNT113 in Kombination mit...

Company Announcement Net sales of DARZALEX® in the third quarter of 2026 totaled USD 4,239 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity...

LOUISVILLE, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced multiple presentations at CHEST 2026 highlighting how...

Company announcement no. 39 - 2613 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway...

PORTLAND, Maine, Oct. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets...

COPENHAGEN, Denmark, October 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase...